Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI–IT/MS, 1H, 13C and 1H–1H COSY NMR
Authors:
Open Access
- 1 October 2014
- journal article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 4 (5) , 339-344
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- STABILITY INDICATING HPLC METHOD FOR THE DETERMINATION OF ESLICARBAZEPINE ACETATE AND ITS IMPURITIES IN BULK DRUGS AND PHARMACEUTICAL DOSAGE FORMSJournal of Liquid Chromatography & Related Technologies, 2012
- Highly efficient, selective, sensitive and stability indicating RP-HPLC–UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2012
- Development of liquid chromatographic enantiomer separation methods and validation for the estimation of (R)-enantiomer in eslicarbazepine acetateJournal of Pharmaceutical and Biomedical Analysis, 2011
- Enantioselective Assay for Therapeutic Drug Monitoring of Eslicarbazepine Acetate: No Interference With Carbamazepine and Its MetabolitesTherapeutic Drug Monitoring, 2010
- Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasmaAnalytical and Bioanalytical Chemistry, 2010
- Enantioselective HPLC‐UV method for determination of eslicarbazepine acetate (BIA 2‐093) and its metabolites in human plasmaBiomedical Chromatography, 2007
- Eslicarbazepine Acetate (BIA 2-093)Neurotherapeutics, 2007